Anticoagulation Therapy in Children

ABSTRACT

Thromboembolic events (TEs) in children are rare but are becoming a recognized cause of morbidity and mortality, particularly in children with serious underlying primary conditions such as congenital heart disease, cancer, or prematurity. Neonates, infants, and adolescents are most at risk for developing TEs among children, and the presence of a central venous line or intra-arterial catheter is the most significant risk factor for TEs in children. Hemostatic differences between children and adults affect both the pathophysiology of the thrombotic process and the response to anticoagulant therapy. In this article, we focus on the impact of the developmental hemostatic system on responses to anticoagulants in children. The most commonly used anticoagulants in children are unfractionated heparin, low-molecular-weight heparins, and warfarin. Minimal experience exists with the use of the new antithrombotic agents in children. As the anticoagulant treatment used for TEs in children is largely adopted from clinical trials performed in adult populations, well-designed prospective trials are required to establish the optimal therapy for children with TEs.

KEYWORDS

Thrombosis - thromboembolism - children - anticoagulants - heparin

REFERENCES

• 1 Andrew M, David M, Adams M. et al . Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE.  Blood . 1994;  83 1251-1257
• 2 van Ommen H C, Heijboer H, Büller H R, Hirasing R A, Heijmans H SA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.  J Pediatr . 2001;  139 676-681
• 3 Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutanous cardiac catheterization in children.  Circulation . 1974;  50 565-569
• 4 deVeber G, Andrew M, Canadian Pediatric Ischemic Stroke Study Group. Cerebral sinovenous thrombosis in children.  N Engl J Med . 2001;  345 417-423
• 5 Schoenberg B S, Mellinger J F, Schoenberg D F. Cerebrovascular disease in infants and children: a study of incidence, clinical features, and survival.  Neurology . 1978;  28 763-768
• 6 Broderick J, Talbot T G, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage.  J Child Neurol . 1993;  8 250-255
• 7 deVeber G, Monagle P, Chan A. et al . Prothrombotic disorders in infants and children with cerebral thromboembolism.  Arch Neurol . 1998;  55 1539-1543
• 8 Andrew M, David M, deVeber G, Brooker L A. Arterial thromboembolic complications in paediatric patients.  Thromb Haemost . 1997;  78 715-725
• 9 Andrew M, Paes B, Milner R. et al . Development of the human coagulation system in the healthy premature infant.  Blood . 1988;  72 1651-1657
• 10 Andrew M, Paes B, Milner R. et al . Development of the human coagulation system in the full-term infant.  Blood . 1987;  70 165-172
• 11 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood.  Blood . 1992;  8 1998-2005
• 12 Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin.  Thromb Haemost . 1994;  72 836-842
• 13 Schmidt B, Ofosu F, Mitchell L, Brooker L, Andrew M. Anticoagulant effects of heparin in neonatal plasma.  Pediatr Res . 1989;  25 405-408
• 14 Chan A K, Berry L R, Monagle P T, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.  Thromb Haemost . 2002;  87 606-613
• 15 Hirsh J, Warkentin T E, Shaughnessy S G. et al . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest . 2001;  119 S64-S94
• 16 Vieira A, Berry L, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation.  Thromb Res . 1991;  63 85-98
• 17 Schmidt B, Buchanan M R, Ofosu F, Brooker L, Hirsh J, Andrew M. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis.  Thromb Haemost . 1988;  60 289-292
• 18 Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan M R. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs.  Thromb Res . 1988;  52 517-527
• 19 Streif W, Mitchell L G, Andrew M. Antithrombotic therapy in children.  Curr Opin Pediatr . 1999;  11 56-64
• 20 Andrew M, Marzinotto V, Massicotte P. et al . Heparin therapy in pediatric patients: a prospective cohort study.  Pediatr Res . 1994;  35 78-83
• 21 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children.  Chest . 2001;  119 S344-S370
• 22 Ranze O, Ranze P, Magnani H N, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients-a review of the literature and a new case treated with danaparoid sodium.  Eur J Pediatr . 1999;  158(Suppl 3) S130-S133
• 23 Severin T, Sutor A H. Heparin-induced thrombocytopenia in pediatrics.  Semin Thromb Hemost . 2001;  27 293-299
• 24 Schmugge M, Risch L, Huber A R, Benn A, Fischer J E. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients (Abst).  Pediatrics . 2002;  109 E10
• 25 Deitcher S R, Topoulos A P, Bartholomew J R, Kichus-Chrisant M R. Lepirudin anticoagulation for heparin-induced thrombocytopenia.  J Pediatr . 2002;  140 264-266
• 26 Nguyen T N, Gal P, Ransom J L, Carlos R. Lepirudin use in a neonate with heparin-induced thrombocytopenia.  Ann Pharmacother . 2003;  37 229-233
• 27 Avioli L. Heparin induced osteoporosis: an appraisal.  Adv Exp Med Biol . 1975;  52 375-387
• 28 Dix D, Andrew M, Marzinotto V. et al . The use of low-molecular-weight heparin in pediatric patients: a prospective cohort study.  J Pediatr . 2000;  136 439-445
• 29 Albisetti M, Andrew M. Low-molecular-weight heparin in children.  Eur J Pediatr . 2002;  161 71-77
• 30 Weitz J I. Low-molecular-weight heparins.  N Engl J Med . 1997;  337 688-698
• 31 Massicotte P, Adams M, Marzinotto V, Brooker L A, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.  J Pediatr . 1996;  128 313-318
• 32 Vieira A, Ofosu F, Andrew M. The activity of low-molecular-weight heparin (CY222) in neonatal plasma.  Thromb Haemost . 1991;  63 85-98
• 33 Andrew M, Ofosu F, Brooker L, Buchanan M. The comparison of the pharmacokinetics of a low-molecular-weight heparin in the newborn and adult pig.  Thromb Res . 1989;  56 529-539
• 34 Massicotte P, Julian J A, Gent M. et al . An open-label randomized controlled trial of low-molecular-weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.  Thromb Res . 2003;  109 85-92
• 35 Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low-molecular-weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases.  Eur J Pediatr . 1999;  158(Suppl 3) S134-S139
• 36 Massicotte P, Julian J A, Gent M. et al . An open-label randomized controlled trial of low-molecular-weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.  Thromb Res . 2003;  109 101-108
• 37 Revel-Vilk S, Sheratkumar A, Massicotte P. et al . Natural history of arterial and venous thrombosis in children treated with low-molecular-weight heparin. A longitudinal study by Doppler ultrasound (Abst).  Blood . 2002;  100 279a
• 38 Hofmann S, Knoefler R, Lorenz N. et al . Clinical experiences with low-molecular weight heparins in pediatric patients.  Thromb Res . 2001;  103 345-353
• 39 Crowther M A, Berry L R, Mongale P T, Chan A K. Mechanism responsible for the failure of protamine to inactivate low-molecular-weight heparin.  Br J Haematol . 2002;  116 178-186
• 40 Ryn-McKenna J, Cai L, Ofosu F A, Hirsh J, Buchanan M R. Neutralization of enoxaparine-induced bleeding by protamine sulfate.  Thromb Haemost . 1990;  63 271-274
• 41 Tait D P. Does low-molecular-weight heparin cause bleeding?.  Thromb Haemost . 1997;  78 1422-1425
• 42 Hirsh J, Dalen J E, Anderson D R. et al . Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.  Chest . 2001;  119 S8-S21
• 43 Massicotte P, Leaker M, Marzinotto V. et al . Enhanced thrombin regulation during warfarin therapy in children compared to adults.  Thromb Haemost . 1998;  80 570-574
• 44 Andrew M, Monagle P T, Brooker L. Developmental hemostasis: relevance to thromboembolic complication in pediatric patients. In: Andrew M, Monagle PT, Brooker L, eds. Thromboembolic Complications During Infancy and Childhood Hamilton, Ontario: BC Decker 2000: 5-46
• 45 Andrew M, Mongale P, Brooker L. Oral anticoagulant therapy in pediatric patients. In: Andrew M, Monagle PT, Brooker L, eds. Thromboembolic Complications During Infancy and Childhood Hamilton, Ontario: BC Decker 2000: 321-356
• 46 Buck M L. Anticoagulation with warfarin in infants and children.  Ann Pharmacother . 1996;  30 1316-1322
• 47 Andrew M, Marzinotto V, Brooker L A. et al . Oral anticoagulation therapy in pediatric patients: a prospective study.  Thromb Haemost . 1994;  71 265-269
• 48 Tait R C, Ladusans E J, el-Metall M, Patel R G, Will A M. Oral anticoagulation in paediatric patients: dose requirements and complications.  Arch Dis Child . 1996;  74 228-231
• 49 Streif W, Andrew M, Marzinotto V. et al . Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients.  Blood . 1999;  94 3007-3014
• 50 Schmidt B, Andrew M. Report of Scientific and Standardization Subcommittee on Neonatal Hemostasis Diagnosis and Treatment of Neonatal Thrombosis.  Thromb Haemost . 1992;  67 381-382
• 51 Marzinotto V, Monagle P, Chan A. et al . Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting.  Pediatr Cardiol . 2000;  21 347-352
• 52 Crowther M A, Julian J, McCarty D. et al . Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.  Lancet . 2000;  356 1551-1553
• 53 Hooshang T, Capitanio M. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy.  Radiology . 1990;  176 728-730
• 54 Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long-term warfarin therapy (Abst).  Thromb Haemost . 1999;  81(Suppl) 1333a
• 55 Ansell J E, Weitz J I, Comerota A J. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism.  Hematology (Am Soc Hematol Educ Program) . 2000;  266-284
• 56 Bauer K A. Selective inhibition of coagulation factors: advances in antithrombotic therapy.  Semin Thromb Hemost . 2002;  28(Suppl 2) 15-24
• 57 Markwardt F. Development of direct thrombin inhibitors in comparison with glycosaminoglycans.  Semin Thromb Hemost . 2001;  27 523-530
• 58 Prisco D, Flaciani M, Antonucci E, Gensini G F. Hirudins for prophylaxis and treatment of venous thromboembolism.  Semin Thromb Hemost . 2001;  27 543-549
• 59 Eriksson B I, Ekman S, Lindbratt S. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg Am . 1997;  79 326-333
• 60 Eriksson B I, Wille-Jørgensen P, Kalebo P. et al . A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
• 61 Schiele F, Lindgaerde F, Eriksson H. et al . Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicenter prospective dose-ranging randomized trial.  Thromb Hemost . 1997;  77 834-838
• 62 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood . 2000;  96 846-851
• 63 Boshkov L K, Thomas G, Kirbi A. et al . Pharmacokinetics of argatroban infusion in a 6-month-old congenital cardiac patient with previously diagnosed heparin-induced thrombocytopenia (Abst).  Blood . 2002;  100 278a
• 64 Herbert J M, Herault J P, Bernat A. et al . Biochemical and pharmacological properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide.  Blood . 1998;  91 4197-4205
• 65 Turpie A GG, Bauer K A, Eriksson B I, Lassen M R. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.  Lancet . 2002;  359 1721-1726
• 66 Elalamy I, Lecrubier C, Potevin F. et al . Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia.  Thromb Haemost . 1995;  74 1384-1385
• 67 Spanier T B, Chen J M, Oz M C. et al . Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.  J Thorac Cardiovasc Surg . 1998;  116 860-869
• 68 Lee A, Agnelli G, Büller H. et al . Dose-response study of recombinant factor VIIa/tissue-factor inhibitor recombinant nematode anticoagulant protein C2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.  Circulation . 2001;  104 74-78
• 69 Barrington K J. Umbilical artery catheters in the newborn: effect of catheter materials [review].  Cochrane Database Syst Rev 2000;CD000949 .
• 70 Pierce C M, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children.  Intensive Care Med . 2000;  26 967-972
• 71 Klement P, Du Y J, Berry L, Andrew M, Chan A K. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex.  Biomaterials . 2002;  23 527-535